Beyond Air, Inc. is a U.S.-based medical technology company built around its LungFit® platform, which generates nitric oxide for hospital and clinical use. Its commercial focus has been on LungFit® PH, while it also maintains earlier-stage programs in oncology through Beyond Cancer and in neurology through NeuroNOS. The company markets directly to hospitals and healthcare systems, using field sales and clinical specialists to support adoption and training. Beyond Air remains in an early commercialization phase and is still funding product rollout, clinical development, and pipeline advancement.
−337,9 %
3,3 %
−433,0 %
+107,3 %
3.80
3.59
| % | |
|---|---|
| Commercial respiratory device platform | 85% LungFit® PH systems and related consumables used to deliver nitric oxide in hospital settings. |
| Clinical services and deployment support | 10% Training, field support, and implementation services that help hospitals adopt and use the system. |
| Pipeline development programs | 5% Preclinical and clinical-stage programs in oncology and neurology that are not yet material revenue drivers. |
Beyond Air sells primarily to hospitals and healthcare providers that use LungFit® PH for patient care, with revenue...
Buy LungFit® PH systems and consumables for clinical use; they matter because current revenue growth is driven by additional hospital contracts.
Accessed through TrillaMed to broaden procurement into Department of Defense and VA hospitals.
Buy or influence purchasing decisions across multiple hospitals to speed adoption and improve scale.
Support expansion into non-U.S. markets where local distribution and regulatory access are needed.
Potential future buyers of NeuroNOS or Beyond Cancer therapies if clinical development succeeds.
The company is headquartered in the United States and manages invoicing and cash collection from Garden City, New York,...
Beyond Air is focused on expanding commercial adoption of LungFit® PH while conserving cash and reducing operating...
The company needs recurring product revenue from its approved platform to offset operating losses and support the business.
Management disclosed substantial doubt about going concern and expects additional funding within one year.
Future growth depends on expanding beyond the U.S. while managing local market access and distribution complexity.
Beyond Cancer and NeuroNOS provide long-term optionality but require capital and clinical validation.
Beyond Air faces significant going-concern and financing risk because it continues to generate losses and has stated...
Management disclosed substantial doubt about the ability to continue as a going concern and said additional funding will be required within one year.
LungFit® PH depends on physician, hospital, and payor acceptance, and pricing pressure can limit margins and sales growth.
The company relies on Spartronics and Medisize for commercial manufacturing and on logistics providers for warehousing and distribution.
Beyond Cancer and NeuroNOS are precommercial programs with no FDA-approved therapies in their target areas, so success is uncertain.
The company stores PII and PHI and depends on IT systems that could be disrupted or breached.
Global operations and outsourced manufacturing expose the business to war, natural disasters, pandemics, and transport interruptions.
NUMD · Surgical & Medical Instruments & Apparatus
BAX · Surgical & Medical Instruments & Apparatus
BYSI · Pharmaceutical Preparations
BNBX · Finance Services
BDPT · Pharmaceutical Preparations
UTHR · Pharmaceutical Preparations
United Therapeutics is a U.S.-based biopharmaceutical company focused on therapies for pulmonary arterial hypertension and other serious rare diseases, along with organ manufacturing technologies.
: 11/08/2026